105 related articles for article (PubMed ID: 16934364)
21. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
23. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
24. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
25. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy.
Ferrer M; Span SW; Vischioni B; Oudejans JJ; van Diest PJ; de Winter JP; Giaccone G; Kruyt FA
Clin Lung Cancer; 2005 Jan; 6(4):250-4. PubMed ID: 15694018
[TBL] [Abstract][Full Text] [Related]
26. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Nørøxe DS; Wallerek S; Sørensen JB
Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K; Laskin J; Ho C
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
31. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
32. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
33. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719
[TBL] [Abstract][Full Text] [Related]
37. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
39. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL
Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
